GLOBAL HEALTH LTD Results Analysis-Q2FY2027
MEDANTA Financial performance and key operating metrics (Consolidated) : Operating Revenue for Q2FY27 is Rs. 1,469 Crs., 33.64% growth YoY, Total Income is Rs. 1,493 Crs., 33.4% growth YoY, EBITDA is Rs. 370 Crs., 60.22% growth YoY, EBITDA Margin is 25.19% improved by 418 Basis points YoY, PBT Rs. 295 Crs. 47.56% growth YoY, PAT Rs. 219 Crs. 38.35% growth YoY. On QoQ basis Op. Revenue is up by 12.65%, Total Income is up by 12.55%, EBITDA is up by 29.06%, PBT is up by 38.25% PAT is also up by 39.36%. Operating KPIs (network) : IP volumes +30% YoY; OP volumes +38% YoY, Occupied bed days +22%; occupancy 67% on expanded base (vs 64%), ARPP: INR 2.06 lakh (+3% YoY), driven by “favorable case mix and increasing contribution from high-acuity specialties” International patient revenue: INR 993m (+30% YoY) OPD pharmacy revenue: INR 699m (+53% YoY) Noida inflection: Cluster 2 EBITDA surge was explicitly attributed to Noida breakeven and “robust operational performance of Lucknow and Patna.” Expansion pipeline now: “6 new greenfield hospitals” (including Ghaziabad). Bed addition plan: 3,450 beds over next few years, taking network to 7,600+ beds (near doubling). Planned capex: INR 6,000+ crore over 4–5 years, including new hospitals, expansions at existing facilities, and supporting infrastructure. Net cash surplus: INR 7,815m (Sep 30, 2026) vs INR 5,906m (Mar 31, 2026).



















